Expert Insights on the Potential for Triplet Regimens in RCC

Shilpa Gupta, MD

<br /> Shilpa Gupta, MD, assistant professor in the Hematology, Oncology, and Transplantation Division at the University of Minnesota, discusses the potential for triplet regimens in the treatment of patients with renal cell carcinoma.

Shilpa Gupta, MD, assistant professor in the Hematology, Oncology, and Transplantation Division at the University of Minnesota, discusses the potential for triplet regimens in the treatment of patients with renal cell carcinoma (RCC).

According to Gupta, preliminary safety data is needed for triplet regimens in RCC. Data in different tumor types has shown that combinations may be more effective, but not as safe.